HomeFacilitiesInfrastructure

Infrastructure

What is the Unique CEGIIR Infrastructure? Specific and unique infrastructure is housed in the Health Research Innovation Facility and in the Zeidler Ledcor Gastrointestinal Health Centre, including:

  1. Tissue storage and processing facilities for all manner of histological and immunologic assessments.
  2. A genomics centre for genotyping and mutation analysis. Under the supervision of Dr. Cox, this facility provides genotypic and phenotypic information about the patients, which are then linked through the CEGIIR database to tissue samples and patient clinical histories. This facility is also an important component of the Centre for Inherited Liver Disease which is being established in Medical Genetics, and will be available to others in the Faculty.
  3. Molecular biology research laboratories for Drs. Taylor, Madsen and Dieleman and a microbiology satellite facility. These facilities permit pursuing the molecular and microbiological biomedical studies necessary to identify the infectious microbial agents associated with these diseases.
  4. Clinical laboratory space in the Zeidler Centre for the group of clinical researchers and nurses of the Gastrointestinal and Liver Disease Research Group (GILDR), as well as other clinical interaction facilities and patient interview rooms.
  5. A bioinformatics infrastructure housed in the Zeidler Centre.
  6. An advanced research endoscopy facility located in the University of Alberta Hospital to derive serum, intestinal and liver samples from research populations.
  7. A BSL3 laboratory to isolate, characterize and formulate diagnostic tests for the human betaretrovirus. This facility is located with the viral Hepatitis research group.
  8. Clinical science research programs which include molecular profiling of human tissues to serve as diagnostic tools and to predict clinical disease progression or the development of cancer. Drs. Sawyer, Cass, Mackey, and C Wong have extensive expertise in molecular profiling, predicting response to treatment and tailoring of therapy to individual disease profiles.
  9. Profiling of in vitro and animal disease models which provides a molecular fingerprint to link microbial infection with the disease processes.
  10. Phase one and advanced clinical trails of innovative therapeutic modalities which are identified as a beneficial consequence of this molecular profiling and be conducted through the infrastructure developed in the Zeidler Building.
  11. Developed databases, used by Dr. Jacobs to determine and model the magnitude of favourable economic and health outcomes achieved with interventions related to specific disorders.